Atrium Health
Atrium Health
Charlotte, North Carolina, United States23 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Geriatric Distal Femur | Femoral Fractures, Femoral Fractures, Distal, Leg Injuries, bone fracture, injury | Recruiting | Not applicable | 2026-09-30 | NCT07237191 | |
| A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Phase 3 | 2026-09-25 | NCT07196748 | |
| A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-25 | NCT07196722 | |
| A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-09-25 | NCT07149857 | |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT06852222 | |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-09-25 | NCT06667076 | |
| INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Shock, Cardiogenic, cardiovascular disorder, heart disorder, heart failure, ischemic disease, myocardial infarction, myocardial ischemia, systolic heart failure, vascular disorder | Not yet recruiting | Not applicable | 2026-09-10 | NCT06965504 | |
| Molecular Assessment and Profiling of Liver Transplant Recipients | Biomarkers; Liver Transplantation | Active, not recruiting | Not stated | 2026-09-03 | NCT04793360 | |
| Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease | Active, not recruiting | Phase 3 | 2026-08-25 | NCT04084080 | |
| Primary Care Implementation and Evaluation of Coach McLungs | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Not applicable | 2026-08-11 | NCT05059210 | |
| GORE® ENFORM Biomaterial Product Study | Hernia, Hernia, Abdominal, Hernia, Diaphragmatic, Hernia, Ventral, Incisional Hernia, Internal Hernia, Pathologic Processes, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Surgical Wound, hiatus hernia, injury | Recruiting | Not applicable | 2026-07-30 | NCT04718168 | |
| Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urological Manifestations, overactive bladder, urinary bladder disorder, urinary system disorder | Recruiting | Not applicable | 2026-07-13 | NCT07195656 | |
| Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 3 | 2026-06-09 | NCT05135091 | |
| Evaluation of the GORE® Ascending Stent Graft | Acute Aortic Syndrome, Aneurysm, Aneurysm, False, Aortic Dissection, Dissection, Blood Vessel, aortic aneurysm, aortic disorder, cardiovascular disorder, thoracic aortic aneurysm, vascular disorder | Enrolling by invitation | Not applicable | 2026-05-29 | NCT05800743 | |
| Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 1 | 2026-04-23 | NCT05871606 | |
| PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia | Arterial Occlusive Diseases, Chronic Disease, Chronic Limb-Threatening Ischemia, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, ischemic disease, peripheral arterial disease, peripheral vascular disease, vascular disorder | Recruiting | Not applicable | 2026-04-16 | NCT05313165 | |
| Venclose digiRF System Post Market Study | chronic venous insufficiency | Active, not recruiting | Not applicable | 2026-03-18 | NCT05504070 | |
| A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-01-16 | NCT04586426 | |
| A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) | Epileptic Syndromes, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, temporal lobe epilepsy | Recruiting | Phase 1 / Phase 2 | 2026-01-07 | NCT06422923 | |
| Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | cardiovascular disorder, heart disorder, heart failure | Active, not recruiting | Not stated | 2025-11-20 | NCT03970343 | |
| A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease, thalassemia | Enrolling by invitation | Not stated | 2025-04-02 | NCT06363760 | |
| A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer | Carcinoma, Ductal, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm | Active, not recruiting | Not stated | 2025-02-12 | NCT03899649 | |
| A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease | Active, not recruiting | Phase 1 / Phase 2 | 2025-01-31 | NCT04853576 |